Ergomotion Launches Direct-to-Consumer, Easy to Use and Affordable Adjustable Bases, Designed to Encourage a Healthy Lifestyle
21.12.2020 22:40:00 EET | Business Wire | Press release
Ergomotion, the largest manufacturer of adjustable bases worldwide, has launched Quest, a new product designed to empower a proactive healthy lifestyle with in-home solutions, and their first entry into an e-commerce site with Direct-to-Consumer products. Quest was created to assist everyone on their wellness journey. The line consists of three different models and a modified design to target consumers at all price points. The product line will be available at local retailers and on Ergomotion’s website.
The new Quest line is a more diverse and advanced product that was developed for a generation that prioritizes health and wellness, including better sleep at an affordable price. As consumers begin to embrace a more holistic approach to health, they want to feel comfortable at home, increasing demand in wellness with home-based products, especially during COVID times. Ergomotion understands the importance of taking better care of yourself during these unprecedented times and the need to enhance the overall quality of life, starting with one’s sleep. Quest adjustable bed bases are equipped with all of your bedroom needs; providing a place to recharge after a long day to simply controlling your bed settings through wand voice activation.
“We’ve been evolving our product collection through a combination of innovative technology and a seamless integration to a healthier lifestyle at a reasonable price,” says Johnny Griggs, Chief Operating Officer at Ergomotion. “The current lifestyle changes that are being experienced worldwide have provided insight to how we are a more health conscious generation, allowing us to focus on what the consumer truly needs and wants in their own home.”
Technology-specific trends are helping the Ergomotion team create products that will be mutli-functional, adaptable, technology infused and overall, more accessible and cost-effective for everyone. The exclusive design benefits of the new Quest product line include:
- Light Weight for the “mobile” customer
- 3 step set-up
- Under 10 min assembly
- Courier Friendly
- Contactless Delivery
- Foldable – Easy Storage
- Wand voice activation
You can learn more about Ergomotion and the Quest product at www.ergomotion.com.
ABOUT ERGOMOTION
Ergomotion, headquartered in Santa Barbara, California, is the largest manufacturer of adjustable bases worldwide. The company’s products are created to provide a holistic wellness solution infused with smart technology to enrich sleep, health, and the overall quality of life. Ergomotion’s adjustable bases are designed to accommodate the industry’s leading mattresses and to seamlessly integrate with existing bed frames. The products have been sold in more than 30 countries to over 170 major brands. Ergomotion is part of the Keeson Technology Corp. family based in Jiaxing City, China. To learn more about Ergomotion visit www.ergomotion.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201221005690/en/
Contact information
Cynthia Murga
cmurga@lambert.com
Direct: 713-935-5766
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces the European Commission Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 23:42:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meury, President and Chief Executive Officer, Incyte. “As the first PD-1 immunotherapy approved in Europe in combination with platinum-based chemotherapy in the first-line setting, Zynyz helps expand the standard-of-care options available to clinicians and underscores our commitment to delivering innovative medicines that can have an impact for patients.” The EC decision follows the January 2026 positive opinion received from the European Medicines Agency’s Committee f
Dfns Launches Payouts6.3.2026 22:27:00 EET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 21:23:00 EET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 19:30:00 EET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services6.3.2026 15:00:00 EET | Press release
Today, Sutherland announced the launch of Sutherland FinAI Hub, an enterprise Agentic AI platform built exclusively for Banking and Financial Services. As financial institutions accelerate AI adoption, many initiatives remain confined to pilots, unable to scale across legacy systems and core operations. Sutherland FinAI Hub is designed to help close that gap. FinAI Hub is an innovation ecosystem where Sutherland works with clients to design, prototype, and scale Agentic AI workflows across core operations. At launch, the platform brings together a large and expanding workforce of domain-trained AI agents purpose-built for financial institutions, supporting functions across retail banking, payments, cards, consumer and commercial lending, servicing, back office, risk and compliance functions. These modular agents can operate independently or be orchestrated across end-to-end workflows spanning onboarding, KYC, AML, fraud, underwriting, payments, disputes, servicing, and collections. For
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom